A I S Resources (OTC:AISSF) Stock, Quote.Headers.trade-ideas

A I S Resources Ltd is an exploration company. It has focused on the evaluation of mineral properties. It acquires prospective exploration projects and enhances their value by defining the mineral resource with a view to attracting joint venture partners and enhancing the value of its portfolio. The company is developing prospective lithium projects in Argentina, and gold projects located in prolific Australian gold mining regions.

Latin America

News

Penny Stocks

Global

Markets

AISSF

GNENF

LTHM

OROCF

SPEYF

Spey Resources is starting a magnetotelluric survey of its Lithium Triangle flagship to identify drill targets and start a resource estimate.

Lithium Explorer To Start Geophysical Survey At Argentina Project

Intraday Update

Movers

Trading Ideas

AAEEF

AAVMY

ABEV

ABGSF

ABMD

ABTX

ACCFF

ACCYY

ACHV

ACNB

ACRFF

ACRGF

ACSAY

ACST

ACTG

ADMA

ADTN

ADVZF

AERI

AFLYY

AGCO

AGEEF

AGESY

AGLXY

AHFD

AHKSY

AHOTF

AICAF

AINV

AIPUY

AIRG

AIRYY

AKO-A

AKZOY

ALDX

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALEX

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLY

ALOT

ALSN

ALTM

ALXEF

ALXN

AMCR

AMHPF

AMKBF

AMKBY

AMNB

AMPH

AMRN

AMSLF

ANAT

ANGO

ANIP

Australia and New Zealand Banking Group Limited

ANZBY

ANZFF

APELY

APEX

APHA

APTS

ARCB

ARCC

ARGGY

ARGO

ARLP

ARNA

ARNGF

AROC

ARREF

ARRRF

Stocks That Hit 52-Week Lows On Friday

A I S Resources Ltd

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Astera Labs</strong>.</p>
<p>Looking at options history for Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) we detected 15 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 26% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $200,701 and 12, calls, for a total amount of $663,270.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $70.0 for Astera Labs over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Astera Labs's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Astera Labs's significant trades, within a strike price range of $35.0 to $70.0, over the past month.</p>
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727115353_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.3</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$50.00</td>
<td>$108.0K</td>
<td style="text-align: right;">117</td>
<td style="text-align: right;">266</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$52.50</td>
<td>$93.0K</td>
<td style="text-align: right;">443</td>
<td style="text-align: right;">972</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$5.2</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$52.50</td>
<td>$87.0K</td>
<td style="text-align: right;">443</td>
<td style="text-align: right;">786</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$52.50</td>
<td>$74.5K</td>
<td style="text-align: right;">443</td>
<td style="text-align: right;">445</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$24.5</td>
<td>$23.2</td>
<td>$23.2</td>
<td>$35.00</td>
<td>$71.9K</td>
<td style="text-align: right;">149</td>
<td style="text-align: right;">31</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.</p>
<p>After a thorough review of the options trading surrounding Astera Labs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Astera Labs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,750,919, the ALAB's price is up by 0.48%, now at $50.75. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Astera Labs</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $55.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Overweight with a revised price target of $55. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Astera Labs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

ALAB

This Is What Whales Are Betting On Astera Labs

<p>Financial giants have made a conspicuous bearish move on Lumen Technologies. Our analysis of options history for Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 23% of traders were bullish, while 69% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $304,011, and 8 were calls, valued at $1,042,934.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $1.0 and $10.0 for Lumen Technologies, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Lumen Technologies's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lumen Technologies's whale activity within a strike price range from $1.0 to $10.0 in the last 30 days. </p>
<h3>Lumen Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727115348_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$7.00</td>
<td>$170.2K</td>
<td style="text-align: right;">709</td>
<td>5.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$7.00</td>
<td>$170.0K</td>
<td style="text-align: right;">709</td>
<td>2.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.69</td>
<td>$1.7</td>
<td>$7.00</td>
<td>$170.0K</td>
<td style="text-align: right;">709</td>
<td>1.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.69</td>
<td>$1.69</td>
<td>$7.00</td>
<td>$169.0K</td>
<td style="text-align: right;">709</td>
<td>5.0K</td>
</tr>
<tr>
<td>LUMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.68</td>
<td>$1.68</td>
<td>$7.00</td>
<td>$167.6K</td>
<td style="text-align: right;">709</td>
<td>3.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lumen Technologies</h3>
<p>With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 has shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.</p>
<p>Having examined the options trading patterns of Lumen Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Lumen Technologies's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 9,235,524, the LUMN's price is up by 5.86%, now at $7.05. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 36 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lumen Technologies with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


LUMN

Spotlight on Lumen Technologies: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Morgan Stanley</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Morgan Stanley.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 12% bullish and 87%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $115,490, and 6 are calls, for a total amount of $341,396.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $109.0 for Morgan Stanley over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Morgan Stanley's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Morgan Stanley's whale trades within a strike price range from $85.0 to $109.0 in the last 30 days. </p>
<h3>Morgan Stanley 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727115343_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.19</td>
<td>$1.06</td>
<td>$1.16</td>
<td>$107.00</td>
<td>$105.3K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.17</td>
<td>$1.17</td>
<td>$107.00</td>
<td>$81.9K</td>
<td>0</td>
<td>2.5K</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.35</td>
<td>$85.00</td>
<td>$81.7K</td>
<td>235</td>
<td>264</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.18</td>
<td>$1.18</td>
<td>$107.00</td>
<td>$52.6K</td>
<td>0</td>
<td>3.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$1.1</td>
<td>$1.08</td>
<td>$1.08</td>
<td>$102.00</td>
<td>$41.9K</td>
<td>1.9K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Morgan Stanley</h3>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.</p>
<p>Following our analysis of the options activities associated with Morgan Stanley, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Morgan Stanley</h3>
<ul>
<li>Currently trading with a volume of 1,573,290, the MS's price is down by -0.42%, now at $102.04. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 23 days.</li>
</ul>
<h3>What Analysts Are Saying About Morgan Stanley</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $105.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral, setting a price target of $105. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Morgan Stanley with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


A Closer Look at Morgan Stanley's Options Market Dynamics

<p><strong>Qualcomm Incorporated </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) shares are experiencing a decline Monday after reports surfaced about the company&#8217;s interest in acquiring <strong>Intel Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). Here&#8217;s <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">what you need to know</a>.</p>
<p><strong>What To Know:</strong> The news highlights Qualcomm&#8217;s potential strategic move to bolster its product line and diversify its business through a multi-billion dollar acquisition of Intel. At the same time, <strong>Apollo Global Management</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has proposed a significant investment in Intel.</p>
<p>The Qualcomm-Intel deal, if it materializes, would mark one of the largest mergers in the semiconductor industry, potentially surpassing Microsoft&#8217;s $69 billion acquisition of Activision Blizzard. However, analysts have raised concerns about the financial and regulatory hurdles Qualcomm could face.</p>
<p><strong>Recap:</strong></p>
<ol>
<li><strong>Qualcomm&#8217;s Potential Acquisition of Intel:</strong> Reports indicate that Qualcomm, led by CEO <strong>Cristiano Amon</strong>, is considering acquiring Intel as part of its broader efforts to diversify. The deal would involve merging two of the world's major chipmakers, impacting sectors such as smartphones, PCs and servers. However, industry analysts believe that Qualcomm will face significant antitrust scrutiny, especially given the size and scale of both companies. </li>
<li><strong>Apollo Global's $5 Billion Investment Offer:</strong> Separately, Apollo Global Management has proposed a $5 billion investment in Intel. Apollo and Intel already have a working relationship after Apollo's $11 billion deal earlier this year to acquire a stake in an Intel venture in Ireland. </li>
<li><strong>Intel's Struggles and Recent Developments:</strong> Intel has been facing one of its most challenging periods in decades, with its market value dropping below $100 billion. The company reported dismal second-quarter earnings, which saw an 84% drop compared to the previous year. </li>
</ol>
<p><strong>QCOM Price Action:</strong> Qualcomm&#8217;s shares dropped by 1.37%, currently trading at $166.61 according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-1024x545.png" alt="" class="wp-image-561675" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23134819/QCOM.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>See Also:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/09/40987452/assembly-biosciences-investigational-herpes-treatment-shows-antiviral-efficacy-safety-in-healthy-">Assembly Biosciences&#8217; Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


INTC

QCOM

Why Are QCOM Shares Moving Today?

Boeing Calls New Proposal "Best And Final Offer" To Resolve Machinists Strike

<p><strong>Gilead Sciences Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.</p>
<p>The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">Gilead Unveils &#8216;Remarkable Outcomes&#8217; From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections</a>.</strong></p>
<p>The <a target="_blank" href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due" rel="noreferrer noopener">affected</a> product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.</p>
<p>Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.</p>
<p>The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.</p>
<p>Gilead has reported no adverse events associated with this recall to date.</p>
<p>Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.</p>
<p>Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.</p>
<p>In 2021, <strong>Gilead Sciences </strong>issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they <a target="_blank" href="https://www.benzinga.com/general/biotech/21/12/24452924/gilead-recalls-two-lots-of-remdesivir-due-to-presence-of-glass-particulates" rel="noreferrer noopener">contained glass particulates</a>.</p>
<p>In the second quarter of 2024, Veklury&nbsp;sales decreased 16% year over year to $214 million, primarily due to lower rates of <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">COVID-19-related hospitalizations</a>.</p>
<p><strong>Price Action:</strong> GILD stock is down 0.05% at $83.90 at last check Monday.</p>
<p><em>Image via Unsplash</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" target="_blank" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.</strong></li>
</ul>


Biotech

Equities

Large Cap

Health Care

General

GILD

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

<p><strong>Alibaba Group Holding Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares are trading higher Monday. Here&#8217;s <a href="https://www.benzinga.com/markets/asia/24/09/40986319/chinese-stocks-defy-bidens-auto-import-ban-concerns-rally-to-4-month-highs-as-central-bank-unexpecte">what you need to know</a>.</p>
<p><strong>What to Know:</strong> Alibaba&#8217;s cloud computing unit partnered with <strong>Nvidia Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance autonomous driving for Chinese EV makers, including Li Auto, Great Wall Motor and ZEEKR. This partnership integrates Alibaba&#8217;s Qwen large language models (LLMs) with Nvidia&#8217;s Drive AGX Orin platform, improving in-car AI capabilities. This move may be seen as strategic, especially as China grapples with U.S. sanctions restricting access to advanced semiconductor chips, which impact both Nvidia and Alibaba.</p>
<p><strong>Market Context:</strong> The People's Bank of China (PBoC) recently slashed key interest rates and injected liquidity into the banking system, boosting investor confidence and contributing to a broader rally in Chinese stocks. The rate cuts are part of efforts to stimulate China&#8217;s economy ahead of its National Day Holiday.</p>
<p><strong>BABA Price Action:</strong> BABA is trading at $90.05, reflecting a 1.99% gain according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.</p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-1024x530.png" alt="" class="wp-image-561642" style="width:485px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23132333/BABA-1.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>See Also:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/09/40987155/mullen-automotives-bollinger-motors-powers-up-first-customer-ready-b4-electric-truck-rolls-off-t">Mullen Automotive&#8217;s Bollinger Motors Powers Up: First Customer-Ready B4 Electric Truck Rolls Off The Line In Michigan</a></strong></li>
</ul>
<p><em>Photo courtesy: Alibaba INC.</em></p>


BABA

NVDA

Alibaba Shares Are Trading Higher: What's Going On

<p><strong>Orgenesis Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares are trading lower by 21% to 40 cents during Monday&#8217;s session after the company announced that its Board of Directors has approved a <a href="https://www.benzinga.com/pressreleases/24/09/g40976804/orgenesis-announces-reverse-stock-split">1-for-10 reverse stock split</a>, effective at 5:00 pm ET on September 24.</p>
<p>Orgenesis says this move aims to meet Nasdaq&#8217;s minimum $1.00 bid price requirement. The stock will continue trading under the symbol &#8220;ORGS&#8221; on a split-adjusted basis starting September 25. </p>
<p>The reverse split will reduce the number of outstanding shares from 47.7 million to approximately 4.77 million, while stockholders&#8217; ownership percentages remain unchanged. </p>
<p>The company also announced that fractional shares will be paid out in cash based on the closing price on September 24.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">Qualcomm Takeover Of Intel Is &#8216;Logically Unlikely&#8217; In Face Of Regulatory Challenges, Analyst Says</a></strong></p>
<h2 class="wp-block-heading">Should I Sell My ORGS Stock?</h2>
<p>When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.</p>
<p>Shares of Orgenesis have decreased by 29.34% in the past year. An investor who bought shares of Orgenesis at the beginning of the year would take a loss of $0.05 per share if they sold it today. The stock has fallen 37.67% over the past month, meaning an investor who bought shares on Aug. 1 would see a capital loss of $0.33.</p>
<p>Orgenesis shares have an all-time high of $5.02, representing 1045.86% upside from current levels.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ORGS has a 52-week high of $1.08 and a 52-week low of $0.25.</p>


ORGS

Why Orgenesis (ORGS) Stock Is Down 23% Today

<p><strong>Masimo</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 8.5% loss over the past four weeks.</p>
<p>The sharp upsurge in Masimo&#39;s shares can be attributed to the surprising news regarding the company&#39;s newly elected Board of Directors. On Sept. 19, per a public statement issued from Politan, activist investor Quentin Koffey, and his Politan Capital Management group&#39;s proposed candidates, both won election to the two available Board seats of Masimo. This guarantees that the new independent directors now have a control of the Board. On Sept. 20, the share price of MASI surged as the investors continued to celebrate the news in a positive view that the new Board is likely to be more conscious of and responsive to the investors.</p>
<p>This medical technology company is expected to post quarterly earnings of $0.84 per share in its upcoming report, which represents a year-over-year change of +33.3%. Revenues are expected to be $501.93 million, up 4.8% from the year-ago quarter.</p>
<p>While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.</p>
<p>For Masimo, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.</p>
<p>The stock currently carries a Zacks Rank #2 (Buy).</p>
<p>Masimo is part of the Zacks Medical - Instruments industry. <strong>CVRx</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvrx#NASDAQ">CVRX</a>), another stock in the same industry, closed the last trading session 1.5% lower at $9.11. CVRX has returned 10.9% in the past month.</p>
<p>For CVRx, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.45. This represents a change of -4.7% from what the company reported a year ago. CVRx currently has a Zacks Rank of #3 (Hold).</p>
<p><a href="https://www.zacks.com/stock/news/2339653/masimo-masi-surges-8-7-is-this-an-indication-of-further-gains?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_3%-2339653">To read this article on Zacks.com click here.</a></p>


Earnings

Mid Cap

Small Cap

Analyst Ratings

Tech

CVRX

MASI

Masimo Surges 8.7%: Is This an Indication of Further Gains?

<p><strong>Wells Fargo &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading lower by 2.0% to $55.17 Monday afternoon. The stock is pulling back after rallying last week following the news of the <strong>Federal Reserve&#8217;s</strong> unexpected <a href="https://www.benzinga.com/markets/equities/24/09/40965372/fed-delivers-large-interest-rate-cut-in-bid-to-sustain-labor-market-stocks-gold-set-new-record-h">50-basis-point rate cut</a>.</p>
<p>Wells Fargo&#8217;s sensitivity to interest rate changes and investor speculation about the short-term effects on profitability has caused the stock to be volatile in recent sessions. </p>
<p><strong>What Happened:</strong> Last week&#8217;s larger-than-expected cut lowered the federal funds rate to a range of 4.75% to 5%, which was perceived as a positive development for Wells Fargo. Banks like Wells Fargo typically benefit from lower short-term borrowing costs, as they can access cheaper funding and potentially increase their net interest margins in the near term. </p>
<p>Additionally, lower interest rates tend to stimulate borrowing by consumers and businesses, which could lead to increased loan demand and higher interest income for Wells Fargo. This potential for immediate growth in lending and profitability likely contributed to the stock&#8217;s initial rise, as investors anticipated a more favorable environment for the bank.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/insights/options/24/09/40985016/what-the-options-market-tells-us-about-wells-fargo">What The Options Market Tells Us About Wells Fargo</a></strong></p>
<p>Furthermore, the Federal Reserve&#8217;s statement that inflation was moving sustainably toward 2% added to the market's confidence. As inflation concerns eased, the economic outlook seemed more stable, which would benefit Wells Fargo's business, as consumer and business confidence is critical for maintaining strong lending activity. </p>
<p>The prospect of additional rate cuts, as indicated by the Fed's dot plot, suggested a longer period of easier monetary policy, further fueling the short-term enthusiasm for Wells Fargo stock.</p>
<p><strong>What Else:</strong> Monday&#8217;s subsequent pullback could reflect a more cautious reassessment of the bank&#8217;s long-term outlook. Although lower interest rates reduce short-term borrowing costs, they also typically lead to a decline in long-term rates. This could compress Wells Fargo&#8217;s net interest margins, as the bank earns less on long-term loans while still facing lower yields on its assets. </p>
<p>Over time, the bank&#8217;s ability to generate income from interest on loans could be hampered in a prolonged low-rate environment, reducing profitability. Investors likely became concerned that while the initial rate cut seemed positive, the extended path of rate reductions might hurt Wells Fargo's ability to sustain its earnings over the longer term.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a></strong></p>
<p>Additionally, the Federal Reserve's updated economic projections painted a less favorable picture for future growth. The downward revision in real GDP growth forecasts, coupled with higher unemployment projections through 2026, signaled a weakening economy. </p>
<p>This raised concerns about potential loan defaults, as higher unemployment often leads to increased credit risk. Wells Fargo, which holds large portfolios of consumer and business loans, could face rising delinquencies and losses in a slower economy. </p>
<p>The bank&#8217;s exposure to consumer credit, mortgages and commercial loans means that an economic downturn or a prolonged period of sluggish growth would directly impact its earnings.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">US Services Growth Tops Estimate, Contraction In Manufacturing Worsens: &#8216;Reacceleration Of Inflation&#8217;</a></strong></p>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
<p>By now you're likely curious about how to participate in the market for Wells Fargo &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.</p>
<p>In the the case of Wells Fargo, which is trading at $55.21 as of publishing time, $100 would buy you 1.81 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WFC has a 52-week high of $62.55 and a 52-week low of $38.38.</p>


What's Going On With Wells Fargo (WFC) Stock?

Boeing Increases General Wage By 30%, Boosts 401(K) Match To 100% Of First 8% Of Pay, And Raises Ratification Bonus To $6,000 In IAM Labor Negotiations

<p><strong>Corbus Pharmaceuticals Holdings, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) received reaffirmed buy ratings from both <strong>H.C. Wainwright</strong> and <strong>Oppenheimer</strong> this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">sharp stock decline</a> after <strong>Novo Nordisk</strong>&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) mid-stage data on its obesity drug.</p>
<p><strong>Andres Maldonado</strong> of H.C. Wainwright reiterated a Buy rating for Corbus with an $80 price target, highlighting that Novo's recent challenges with monlunabant, a drug targeting the same receptor as Corbus&#8217; <strong>CRB-913</strong>, should not impact the latter's potential. The stock currently trades below the $20 mark.</p>
<p>Maldonado<a href="https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-corbus-pharmaceuticals-on-crb-913s-potential-and-holistic-pipeline-valuation?utm_source=benzinga.com&amp;utm_medium=referral"> stressed </a>that different drugs within the same class could exhibit unique efficacy and safety profiles.&nbsp;</p>
<ul>
<li><strong><em>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</em></strong></li>
</ul>
<h3 class="wp-block-heading">Oppenheimer And Mizuho Double Down On Corbus' Pipeline</h3>
<p>Oppenheimer also maintained a Buy rating, setting a price target of $88, focusing not only on CRB-913 but also on Corbus' broader assets, especially CRB-701.&nbsp;</p>
<p>Mizuho similarly recommended <a href="https://seekingalpha.com/news/4151904-mizuho-recommends-buying-corbus-following-its-drop-post-novos-obesity-data?utm_source=partner_&amp;utm_medium=referral&amp;feed_item_type=news">buying the dip</a>, viewing the recent 60% stock plunge as an overreaction.&nbsp;</p>
<p>The firm pointed to CRB-701's positive Phase 1 data and sees the company's valuation primarily tied to this Nectin-4-based ADC for cancer treatment, rather than the obesity drug alone.</p>
<p><strong>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d">Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk&#8217;s Cannabinoid-Based Weight Loss Drug Trial Disappoints</a></strong></p>


Cannabis

Price Target

Reiteration

CRBP

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Centene's Health Net Subsidiary Selected For California Medicaid Dental Contract In Los Angeles And Sacramento Counties, Starting July 2025

<p>Piper Sandler  analyst Joseph Catanzaro   maintains Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Overweight and raises the price target from $12 to $15.</p>


BDTX

Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Raises Price Target to $15

<p>Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $103.19, a high estimate of $123.00, and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 12.99% increase from the previous average price target of $91.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114456_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Best Buy Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$107.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Best Buy Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Best Buy Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Best Buy Co analyst ratings.</strong></a></p>
<h2>Delving into Best Buy Co's Background</h2>
<p>With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.</p>
<h3>Best Buy Co: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Challenges:</strong> Best Buy Co's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately <strong>-3.08%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Best Buy Co's net margin excels beyond industry benchmarks, reaching <strong>3.13%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Best Buy Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.4%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Best Buy Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.92%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Best Buy Co's debt-to-equity ratio is below the industry average at <strong>1.32</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 16 Analyst Evaluations For Best Buy Co

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>United Parcel Service</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UPS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for United Parcel Service.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $271,854, and 5 are calls, for a total amount of $313,243.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $110.0 to $145.0 for United Parcel Service over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for United Parcel Service's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Parcel Service's whale activity within a strike price range from $110.0 to $145.0 in the last 30 days. </p>
<h3>United Parcel Service 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114455_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.9</td>
<td>$6.75</td>
<td>$6.9</td>
<td>$140.00</td>
<td>$96.6K</td>
<td>899</td>
<td>142</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.15</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$145.00</td>
<td>$82.4K</td>
<td>2.7K</td>
<td>2.2K</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$130.00</td>
<td>$75.0K</td>
<td>1.6K</td>
<td>151</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$19.25</td>
<td>$18.85</td>
<td>$19.25</td>
<td>$135.00</td>
<td>$67.3K</td>
<td>904</td>
<td>45</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.98</td>
<td>$0.97</td>
<td>$0.98</td>
<td>$145.00</td>
<td>$59.0K</td>
<td>2.7K</td>
<td>882</td>
</tr>
</tbody>
</table>
</p>
<h3>About United Parcel Service</h3>
<p>As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 64% of total revenue while international package makes up 20%. Air and ocean freight forwarding, truckload brokerage, and contract logistics make up the remainder. UPS is currently pursuing "strategic alternatives" for its truck brokerage unit, Coyote, which it acquired in 2015.</p>
<p>Having examined the options trading patterns of United Parcel Service, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>United Parcel Service's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,534,525, the price of UPS is up by 0.14%, reaching $128.78.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 31 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United Parcel Service options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Smart Money Is Betting Big In UPS Options

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>AutoZone</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AZO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for AutoZone.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 20% bullish and 53%, bearish.</p>
<p>Out of all of the special options we uncovered, 10 are puts, for a total amount of $464,107, and 5 are calls, for a total amount of $219,793.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $2650.0 to $3700.0 for AutoZone over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AutoZone's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AutoZone's whale trades within a strike price range from $2650.0 to $3700.0 in the last 30 days. </p>
<h3>AutoZone Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114450_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$36.0</td>
<td>$35.0</td>
<td>$36.0</td>
<td>$2900.00</td>
<td>$86.4K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$77.9</td>
<td>$68.0</td>
<td>$73.71</td>
<td>$3300.00</td>
<td>$73.7K</td>
<td style="text-align: right;">33</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$678.6</td>
<td>$662.0</td>
<td>$678.2</td>
<td>$3700.00</td>
<td>$67.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$88.6</td>
<td>$82.1</td>
<td>$84.0</td>
<td>$3040.00</td>
<td>$58.8K</td>
<td style="text-align: right;">18</td>
<td style="text-align: right;">19</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$93.9</td>
<td>$87.1</td>
<td>$93.9</td>
<td>$3060.00</td>
<td>$56.3K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>
</p>
<h3>About AutoZone</h3>
<p>AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates over 6,300 stores domestically, serving both the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and in some instances, installation. The company also operates internationally, with over 750 stores in Mexico and more than 100 in Brazil.</p>
<h3>AutoZone's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 71,303, the AZO's price is up by 0.73%, now at $3042.63. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>Expert Opinions on AutoZone</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $3275.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for AutoZone, targeting a price of $3350.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $3200. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for AutoZone, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AutoZone Unusual Options Activity

<p>Investors with significant funds have taken a bullish position in Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in CRBP usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 12 options transactions for Corbus Pharmaceuticals. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 50% being bullish and 25% bearish. Of all the options we discovered, 11 are puts, valued at $389,510, and there was a single call, worth $52,400.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $17.5 and $55.0 for Corbus Pharmaceuticals, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Corbus Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Corbus Pharmaceuticals's significant trades, within a strike price range of $17.5 to $55.0, over the past month.</p>
<h3>Corbus Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114445_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRBP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$2.25</td>
<td>$2.6</td>
<td>$30.00</td>
<td>$52.4K</td>
<td>12</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$31.6</td>
<td>$30.3</td>
<td>$30.9</td>
<td>$50.00</td>
<td>$46.3K</td>
<td>2.2K</td>
<td style="text-align: right;">185</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.9</td>
<td>$30.4</td>
<td>$30.9</td>
<td>$50.00</td>
<td>$43.2K</td>
<td>2.2K</td>
<td style="text-align: right;">226</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$17.50</td>
<td>$41.8K</td>
<td>0</td>
<td style="text-align: right;">47</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.8</td>
<td>$30.3</td>
<td>$30.6</td>
<td>$50.00</td>
<td>$36.7K</td>
<td>2.2K</td>
<td style="text-align: right;">261</td>
</tr>
</tbody>
</table>
</p>
<h3>About Corbus Pharmaceuticals</h3>
<p>Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.</p>
<p>Following our analysis of the options activities associated with Corbus Pharmaceuticals, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Corbus Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 2,140,401, the CRBP's price is down by -2.77%, now at $18.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>Professional Analyst Ratings for Corbus Pharmaceuticals</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $67.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for Corbus Pharmaceuticals, targeting a price of $40.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $82.<br />
&#x2A; Consistent in their evaluation, an analyst from Wedbush keeps a Outperform rating on Corbus Pharmaceuticals with a target price of $51.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $82.<br />
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $80.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Corbus Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Spotlight on Corbus Pharmaceuticals: Analyzing the Surge in Options Activity

<p>Ratings for Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) were provided by 28 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $920.14, a high estimate of $975.00, and a low estimate of $780.00. Surpassing the previous average price target of $886.88, the current average has increased by 3.75%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114443_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Costco Wholesale is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$950.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniela Nedialkova</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Neutral</td>
<td>$890.00</td>
<td>$860.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$950.00</td>
<td>$855.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$975.00</td>
<td>$970.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$915.00</td>
<td>$910.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$780.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$915.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$955.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$875.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Announces</td>
<td>Buy</td>
<td>$925.00</td>
<td>-</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$927.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$915.00</td>
<td>$920.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$925.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$800.00</td>
<td>$775.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$905.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$920.00</td>
<td>$890.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$830.00</td>
<td>$765.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$970.00</td>
<td>$940.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$950.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$962.00</td>
<td>$874.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$975.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$900.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$900.00</td>
<td>$850.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Costco Wholesale. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Costco Wholesale compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Costco Wholesale's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Costco Wholesale's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Costco Wholesale analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Costco Wholesale</h2>
<p>Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and enjoys over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 270 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.</p>
<h3>Financial Milestones: Costco Wholesale's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Costco Wholesale showcased positive performance, achieving a revenue growth rate of <strong>9.07%</strong> as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Costco Wholesale's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.87%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Costco Wholesale's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.9%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Costco Wholesale's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.5%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.43</strong>, Costco Wholesale adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COST

Demystifying Costco Wholesale: Insights From 28 Analyst Reviews

<p>In the last three months, 11 analysts have published ratings on EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.73, a high estimate of $6.00, and a low estimate of $4.00. Observing a 2.83% increase, the current average has risen from the previous average price target of $4.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727114434_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive EVgo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>William Grippin</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Legg</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$5.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EVgo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EVgo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for EVgo's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of EVgo's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EVGO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on EVgo analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know EVgo Better</h2>
<p>EVgo owns and operates a public direct current fast-charging network in the us. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the us. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments and independent property owners in order to locate and deploy its EV charging infrastructure.</p>
<h3>Key Indicators: EVgo's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> EVgo's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>31.78%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> EVgo's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-15.47%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> EVgo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-52.49%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> EVgo's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.31%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> EVgo's debt-to-equity ratio is below the industry average. With a ratio of <b>5.86</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EVGO

Analyst Scoreboard: 11 Ratings For EVgo

A.I.S. Resources Limited (TSE:AIS) has released an update. A.I.S. Resources Limited has entered into an option agreement with American Salars Lithi...

AIS Options Lithium Project to American Salars

A.I.S. Resources Limited (TSE:AIS) has released an update. A.I.S. Resources Limited has announced a 1-for-10 reverse stock split effective March 8,...

A.I.S. Resources Initiates Strategic Reverse Split

Ais Resources Ltd (TSE:AIS) has released an update. A.I.S. Resources Limited has announced the strategic appointment of mining entrepreneur John Mc...

AIS Resources Welcomes New Board Member

AIS Resources (TSE:AIS) has released an update. A.I.S. Resources Limited has successfully completed a private placement of convertible debentures w...

A.I.S. Resources Secures Funding Through Private Placement

AIS Resources (TSE:AIS) has released an update. A.I.S. Resources Limited has intensified its gold exploration endeavors in Australia, focusing on t...

AIS Resources Accelerates Australian Gold Exploration

Financing

Press Releases

A.I.S. Resources Options Candela II Interest to American Salars Lithium Inc.

A.I.S. Resources Announces a 1-for-10 Reverse Stock Split

A.I.S. to Focus Efforts on Gold Exploration in Australia

Management

A.I.S. Resources Appoints John McCleery to the Board of Directors

A.I.S. Resources Closes Convertible Debenture Private Placement

A.I.S. Resources Sets New Path for Growth with Australian Gold Exploration Update and Board Appointment

CSE:USLI

TSXV:AIS

A I S Resources

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

A I S Resources

A I S Resources (AISSF) Forecast

A I S Resources (OTC:AISSF) Stock, Quote.Headers.trade-ideas